innoHealth Group in collaboration with Jacqui Wood Cancer Centre, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Emerald Health Biotechnology, Universidad de Córdoba and Hospital Reina Sofía has published the research article titled Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1 in Redox Biology journal.
Cannabidiol (CBD) is a major non-psychotropic phytocannabinoid with pleiotropic effects, being a promise molecule for the treatment of different pathologies including skin diseases. Our study has been focused in researching the molecular mechanisms and targets of CBD on primary human keratinocytes. Transcriptomic (RNA-Seq) and proteomic (SWATH-MS) analysis revealed that CBD was involved in processes such as keratinocyte differentiation, skin development and epidermal differentiation. Furthermore, CBD activated NRF2 weakly and upregulated a subset of NRF2 target genes, highlighting heme oxygenase 1 (HMOX-1). We have showed for the first time that the increased expression of HMOX1 in keratinocytes by CBD is due to the nuclear export and proteosomal degradation of the transcriptional repressor BACH1 and, therefore, in a NRF2 independent manner. Finally, the topical CBD application in mice increased the HMOX-1 and cytokeratines 16 and 17 expression associated with proliferation and wound repair. Altogether, the finding that CBD is a BACH1 inhibitor suggests that its topical use could protect the skin against external insults and it also could be beneficial for skin diseases treatments including atopic dermatitis and keratin disorders.
To read the full article, please click in the next link: https://www.sciencedirect.com/science/article/pii/S2213231719306470?via%3Dihub